StockIQpro
NYSE:APUS

Apimeds Pharmaceuticals US, Inc.

Track all markets on TradingView
Track all markets on TradingView

Apimeds Pharmaceuticals US, Inc. reported net income of −$6.0M in fiscal 2025. Free cash flow was −$9.0M, and the diluted share count rose 37.7%.Summary generated from Apimeds Pharmaceuticals US, Inc.'s SEC filings. Latest annual report filed May 4, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−7.9%
Debt / equityn/a
Free cash flow−$9.0M
FCF marginn/a
Share count change+37.7%

Financials

Fiscal years, $M
Item202320242025
Revenuen/an/an/a
Operating income−1−1−12
Net income−1−1−6
Free cash flown/an/a−9

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations